Kidney Cancer Treatment Acclerated with Personalized Treatment and Genome Analysis Tool

Kidney Cancer Treatment Acclerated with Personalized Treatment and Genome Analysis Tool

Release Date: 02-Aug-2020



Kideny cancer is among the most frequently diagnosed cancer in the whole world. This has led the researchers to incline towardsits treatment more than any other type of cancer. Now-a-days, researchers are inclined towards using personalized medicine approach for the treatment of kidney cancer wth the help of tool that could perform advanced genome analysis. The difference in the treatment response that is noted down from every kidney patient is different from one another and as treatment is decided for the patient without any concern about small change in the genetic sequence. This however leads to difference in the treatment response of the patients.                      

 

A group of researchers at the City of Hope have now started questioning the old ongoing treatment procedure with the modern technologies. According to them, they will start performing compreshensive sequencing of genome and exome for all the patients with stage IV cancer.The primary aim of this particular initiative is to study the genetic profile of each and every patient enrolled in the study and to enable the treatment service that is capable of generating an immune response according to the tumor profile.

 

Normal whole exome sequencing and tumor whole transcriptome sequencing were two different tools that were used to analyse the genome of the patients. Using these respective tools the researchers were able to derive the information about the proteome of the patient. Through the means of the tools available for the researchers, they were dedicated towards identifying the genomic alterations that are correlated with the therapy response.

According to the analysis conducted by the researchers, they were able to extract some useful information. The geneome and proteome analysis performed by them suggested that if a cancer patient carries mutation in the TERT gene, then the patient will not show any response towards immune checkpoint inhibitors. The bifurication for the patients enrolled in the study was perfomed. The patients having their genome profiling were the only one that were included in the study.

 

The researchers inclined towards the study analyzed nearly 19,396 genes and nucleic sequences in order to unravel the treatment plan that could be best for remove the patients from all the sufferings that the cancer of kidney is providing to the patients. The results received from the study reflected that in order to deliver some useful data, large sample sizes studies should be conducted. It will enhance the precision medicine treatment for kidney cancer. Also, the sequencing of the whole exome, reserahcers will expose more target sites for the development of novel therapeutic treatments which in future will control in the epidemic that kidney cancer is causing.

Need custom market research solution? We can help you with that too.